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Summary. Precision medicine, also known as genome-based medicine and personalized medicine, uses knowledge 
of the molecular basis of a disease in order to individualize treatment for each patient. The development of novel, 
powerful, high-throughput technologies has enabled better insight into the genomic, epigenomic, transcriptomic 
and proteomic landscape of many diseases, resulting in the application of personalized medicine approaches in 
healthcare. Research in the field of biomedicine in Serbia has followed the modern trends and has made a great 
contribution to the implementation of genomics in Serbian clinical practice. This is a review of the state of the art of 
scientific achievements and their application, which have paved the way for personalized medicine in Serbia.
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Introduction
Although medicine always aimed to be personalized, a 
true implementation of personalized medicine in healthcare 
practice has only recently started. The fascinating progress 
of molecular genetics has strongly contributed to this great 
achievement of modern medicine. Personalized medicine, 
also known as genome-based medicine and precision medi-
cine, uses knowledge of the molecular basis of a disease in 
order to individualize treatment for each patient. The devel-
opment of novel, powerful, high-throughput technologies 
has enabled better insight into the genomic, epigenomic, 
transcriptomic and proteomic landscape of many diseases, 
resulting in the application of personalized medicine ap-
proaches in their treatment.
One of the most important achievements of personal-
ized medicine is the discovery of novel diagnostic molecular 
markers. Furthermore, numerous newly discovered molecu-
lar markers have contributed to a more precise classifica-
tion of patients into distinct prognostic groups, leading to 
specific, more successful treatment protocols. The develop-
ment of pharmacogenomic platforms and the application of 
molecular-targeted therapy have led to the individualization 
of therapy, tailoring it to the genetic profile of a disease in 
each patient. The ultimate goal of genome-based medicine 
is to develop gene therapy that will cure or prevent a disease 
by targeting disease-causing molecular defects. Additionally, 
cellular and tissue therapies have opened new possibilities 
for the personalized treatment of many patients. There is no 
doubt that we are getting closer to full implementation of 
personalized medicine in everyday clinical practice.
Genomics in the service of the diagnosis of rare diseases
The majority of rare diseases (~80%) are genetic and 
therefore identification of a specific gene defect in a patient is 
important. For over ten years, PCR-based techniques, Sanger 
DNA sequencing and multiplex ligation-dependent probe 
amplification (MLPA) have been used for the complete mo-
lecular diagnosis of monogenic diseases. Thus, the first data 
on molecular genetic characteristics of thalassemia (HBB 
gene), phenylketonuria (PAH gene), tetrahydrobiopterin de-
ficiency (PTS gene) and congenital adrenal hyperplasia (CY-
P21A2gene) were reported for various populations, including 
the Serbian population (Stojiljković et al. 2006; Radmilović 
et al. 2010; Milačić et al. 2015).
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Recently, high-throughput targeted resequencing meth-
odology based on a simultaneous analysis of all clinically 
relevant genes was introduced into routine diagnostic prac-
tice. Clinical exome sequencing enabled the diagnosis of ge-
netically heterogeneous diseases, such as glycogen storage 
diseases, organic acidurias or mitochondriopathies. Using 
next-generation sequencing (NGS) methodology, it became 
possible to precisely identify a genetic defect in one gene 
among a dozen of suspected genes. Moreover, different dis-
eases with partially overlapping clinical manifestations are 
being easily and accurately diagnosed (Skakić et al. 2017).
As a consequence of NGS application, identification 
of novel genetic variants has become a frequent event. To 
assess the pathogenic effect of all genetic variants detected 
for the first time, computational, expressional and/or func-
tional analysis needs to be performed (Stojiljkovic et al. 2009, 
2016; Skakic et al. 2017). Detailed functional characterization 
contributes to the unambiguous diagnostic interpretation of 
novel genetic variants worldwide. Furthermore, given that 
patients with particular genotypes are rare, it is important to 
report clinical observations about variants’ effect on patients’ 
phenotypes in order to contribute to the general knowledge 
about monogenic diseases.
In order to explain genotype-phenotype inconsistencies 
present in monogenic disorders such as phenylketonuria, 
non-coding gene regions should be investigated. Successful 
identification of several novel transcriptional regulators lo-
cated in the promoter, intron and 3’ region of the PAH gene 
shed new light on the fine regulation of PAH expression and 
contributed to a better understanding of PKU phenotype 
complexity (Stojiljkovic et al. 2010; Klaassen et al. 2017).
National databases that collect allele frequencies of clin-
ically relevant genetic variations could be used to study gene 
flow among populations, human demographic history and 
most importantly, to optimize genetic testing in the country. 
The Serbian National Database was developed as a part of the 
FINDbase worldwide database to hold information specific 
to the Serbian population and serve as a valuable source of 
information for genetic specialists and medical doctors in 
Serbia as well as in other countries in southeastern Europe 
(Viennas et al. 2016).
An approach that combines Sanger and next-generation 
sequencing leads to timely and accurate genetic testing, sets 
definite diagnoses and enables rapid implementation of opti-
mal therapy for patients with rare and other genetic diseases.
Personalized medicine in hematological 
malignancies: molecular markers for prognosis and 
follow-up of the disease
Application of the principles of personalized medicine 
is especially useful in the treatment of various types of can-
cer. Individual cancer is characterized by its distinctive and 
unique genetic and epigenetic profile. The study of the ge-
netic basis of cancer contributes not only to a better under-
standing of its etiology, but it also greatly influences common 
clinical practice. Nowadays, standard clinical protocols for 
the treatment of oncological patients cannot be applied with-
out the detection of specific genetic markers, representing 
either important diagnostic/prognostic indictors, or targets 
for the implementation of specific therapeutics. Hemato-
logical malignancies represented the ideal context for the 
implementation of personalized medicine programs. 
Hematological malignancies are cancers of blood-
forming tissues (bone marrow or lymph nodes). There are 
three main types of blood cancers: leukemia, lymphoma and 
multiple myeloma. Hematological cancers are rare diseases 
affecting predominantly the middle-aged and older popula-
tion. Acute lymphoblastic leukemia (ALL) is the most com-
mon type of cancer in children. On the other hand, acute 
myeloid leukemia (AML) is very common in adults, whereas 
in children it is detected in about 15% of cases of all acute 
leukemia. 
Leukemia is a genetic disease of somatic cells that are 
characterized by unlimited proliferation and/or impaired dif-
ferentiation of progenitor cells, leading to the accumulation 
of immature blast cells in the bone marrow and peripheral 
blood, and resulting in hematopoietic failure. 
The application of personalized medicine in the treat-
ment of leukemia first started through the application of mo-
lecular methods for identifying the pretreatment karyotype 
of leukemia patients. Pretreatment karyotype is the most 
reliable tool used for risk stratification and the categoriza-
tion of patients into certain risk groups, and entails the use 
of the appropriate treatment protocol. The most common 
genetic aberrations found in leukemia are translocations, and 
their detection is essential for precise risk stratification. For 
example, in childhood ALL there are four major risk-strati-
fying translocations (BCR/ABL, MLL/AF4, TEL/AML1 and 
E2A/PBX1) whose presence allows the use of contemporary 
protocols, ensuring high-remission rates and long-term free 
survival (Lazic et al. 2010).
By using sensitive methods like reverse transcriptase 
polymerase chain reaction (RT-PCR) analysis, it is possible 
to detect not only common fusions, but also fusions that are 
less frequent (such as rare NUP98/HOXC13 fusion, derived 
from t(11;12)(p15;q13) translocation), and every such case 
can provide new insight in the etiology of the disease itself 
(Tošić et al. 2009). 
It is important to emphasize that common disease-caus-
ing translocations have been used as targets against which 
new, molecular-based therapies have been designed.
Contrary to ALL, AML patients are predominately 
characterized by the presence of normal karyotype (AML-
NK). This cohort of AML patients is characterized as patients 
with intermediate risk. As a result of this imprecise classifi-
cation, the overall survival of adult and pediatric AML-NK 
patients is only 30% and 60%, respectively. However, with 
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the application of new technologies (not only PCR, but DNA 
sequencing as well), new genetic markers with predictive 
values were detected. Some of these markers are mutations 
in fms-related tyrosine kinase-3 (FLT3), nucleophosmin 
(NPM1) and CCAAT/enhancer-binding protein alpha gene 
(CEBPA). Additional data on the mutational status of these 
genes contributed significantly to allocating the leukemia 
patients into the appropriate risk groups (Colovic et al. 2007; 
Krstovski et al. 2010; Kuzmanovic et al. 2012). 
In chronic lymphocytic leukemia (CLL), the malig-
nancy of mature B lymphocytes, the most powerful inde-
pendent prognostic factor, is the somatic hypermutation sta-
tus of rearranged immunoglobulin heavy variable (IGHV) 
genes. In around 50% of cases, the immunoglobulin heavy 
chain (IGH) rearrangements of CLL clones carry somatic 
hypermutations, and these patients suffer from more aggres-
sive disease with shorter time to first treatment and overall 
survival than patients with unmutated IGH rearrangements 
(Karan-Djurasevic et al. 2012). The prognostic value of IGHV 
mutational status, besides its consistent association with 
the clinical behavior of CLL, lies in the fact that it does not 
change over time, and that it can predict the course of the 
disease at the time of diagnosis as well as at any other stage 
(i.e. regardless of the tumor burden).
Furthermore, the configuration of clonotypic IGH re-
arrangement and, hence, the structure of the B cell recep-
tor (BCR) expressed on the surface of CLL cells, provides 
additional prognostic information, particularly in cases ex-
pressing so-called “stereotyped BCRs” (Agathangelidis et al. 
2012). The structure and somatic hypermutation pattern of 
the BCR of the malignant clone represents its specific genetic 
signature. As a result of the enormous progress in CLL im-
munogenetic research in recent years, it is plausible that, in 
addition to IGHV mutational status, the information about 
the clonotypic BCR will soon be included into the risk-strat-
ification systems and, ultimately, contribute to the tailoring 
of individualized treatment modalities.
To overcome the extreme clinical variability of CLL and 
improve individual patients’ prognostication, especially in 
early-stage disease, other cellular and molecular prognostic 
markers have also been identified, some of which have been 
introduced into routine clinical practice (cytogenetic aberra-
tions, CD38 and ZAP-70 expression, TP53 mutations) (Antić 
et al. 2011). Finally, the recent genomic profiling studies of 
CLL patients, based on next-generation sequencing method-
ology, have identified several recurrently mutated genes in 
CLL (e.g. NOTCH1, SF3B1, MYD88, BIRC3, NFKBIE, TP53, 
ATM), some of which exert prognostic relevance even inde-
pendently of IGHV mutational status (Baliakas et al. 2015).
Like no other technical innovation before, the appli-
cation of NGS for the detection of somatic mutations has 
contributed to better understanding the biology of cancer in 
general, and hematological malignancies, as well. The appli-
cation of NGS technology in the analysis of various types of 
leukemia has enabled the detection of previously unknown 
mutations, such as IDH1 and IDH2 mutations, which are 
very frequent in AML (as much as 20%), and which have a 
significant prognostic role (Virijević et al. 2016). Another 
interesting finding obtained through NGS technology is that 
acute leukemias are characterized by a very low number of 
somatic mutations, only 3-5 per patient (Marjanovic et al. 
2016). The somatic mutation number is low even in com-
parison with other hematological malignancies. For example, 
the number of somatic mutations detected in rare primary 
diffuse large B cell lymphoma of central nervous system 
(DLBCL CNS) was up to 46 per patient (Todorović Balint et 
al. 2016). This has led to the conclusion that the epigenetic 
component must be considered as an important factor in the 
pathogenesis of leukemia. 
Gene expression profiling (GEP) represents a technol-
ogy that is very useful for identifying gene expression sig-
natures associated with distinct types of leukemia. Almost 
every type of leukemia (acute or chronic) has its own gene 
expression profile. For example, acute promyelocytic leu-
kemia (APL), characterized by translocation t(15;17), has 
a unique profile. It stands also for AML-NK. It has been 
shown that distinct GEP has a predictive value for relapse 
in AML-NK patients (Hackl et al. 2015). Numerous stud-
ies have revealed that certain genomic and transcriptomic 
profiles are associated with the pathogenesis of leukemia, 
but more importantly, that they have excellent value for ac-
curate diagnosis and prediction of disease outcome. These 
new molecular markers have taken on an important role in 
everyday clinical practice and the treatment of hematologi-
cal malignancies. For instance, in AML-NK, in addition to 
genomic profile, the analysis of the expression level of some 
individual genes, such as WT1, BAALC, MN1, and EVI1, 
is recommended due to their significant prognostic impact 
(Marjanovic et al. 2017). In another type of hematological 
malignancy, in multiple myeloma, the expression of the cere-
blon gene (CBN) can influence prognosis in patients treated 
with modern immunomodulatory drugs (Bila et al. 2016). 
All these findings have led to a deeper insight into the ge-
nomic and transcriptomic landscape of different hematologi-
cal malignancies and, consequently, to the discovery of novel 
prognostic markers and innovative therapeutic strategies, 
resulting in better survival of patients with hematological 
malignancies.
Pharmacogenomics
Pharmacogenomics is a major cornerstone of person-
alized medicine. Pharmacogenomics identify genomic and 
clinical information in order to predict the response to treat-
ment of a person (Pavlovic 2009) and establish guidelines for 
using therapeutics according to the individual’s genomic, 
epigenomic and transcriptomic profile (Mizzi et al. 2017). It 
is the tailoring of drug treatments to people’s genetic makeup. 
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Pharmacogenomics completely changed the old therapeutic 
paradigms of “one dose fits all patients” and “trial-and-error” 
prescription, into a novel, personalized concept of “matching 
the right therapeutic and the right dose to the specific genetic 
signature of the patient”.
Before administering certain drugs to a patient, it is 
mandatory to perform defined pharmacogenomic testing. 
For some drugs, pharmacogenomic analysis is recommended 
but for most drugs, the testing used today is only informa-
tive. Several genomic, epigenomic, transcriptomic and pro-
teomic markers have already been introduced in routine 
diagnostic, prognostic and therapeutic protocols for many 
diseases (Georgitsi et al. 2011; Stojiljkovic et al. 2011).
One of the first clinically recognized pharmacogenomic 
markers, now mandatory for testing prior to administering 
immunosuppressive therapy (6-mercaptopurine, azathio-
prine and thioguanine), is a variation in the TPMT gene 
(thiopurine S-methyltransferase) (Pavlovic and Zukic 2010; 
Pavlovic et al. 2012). Mercaptopurine drugs are used in the 
treatment of various diseases and the doses of these drugs 
are routinely adjusted according to the patient’s TPMT 
genotype in childhood ALL, inflammatory bowel disease 
(IBD), autoimmune diseases and in transplantation medicine 
(Jojić et al. 2003; Dokmanovic et al. 2006, 2008). Further-
more, the variable number of tandem repeats (VNTR) in 
the TPMT promoter is a novel and promising pharmacoge-
nomic marker (Zukić et al. 2010). Testing the number and 
type of the repeats, VNTR architecture can be potentially 
used as a pharmacogenomic marker to predict toxicity due 
to 6-MP treatment in childhood ALL patients (Kotur et al. 
2012). The TPMT promoter VNTR region has the most 
benefit as a pharmacogenomic biomarker at the very begin-
ning of the maintenance therapy for pediatric ALL patients 
(Kotur et al. 2015). The key drug in the intensification phase 
in therapeutic protocols for children with ALL is an antifo-
late chemotherapeutic agent, methotrexate. Implementation 
of pharmacogenomic testing for pharmacogenomic mark-
ers involved in methotrexate metabolism in current proto-
cols will lead to the optimization of pediatric ALL therapy 
(Lazić et al. 2017). Glucocorticoid drugs, due to their abil-
ity to induce apoptosis, are a central component of many 
chemotherapy protocols, including protocols used for the 
treatment of leukemias and IBD. Several pharmacogenomic 
and pharmacotranscriptomic markers have been intensively 
studied in order to avoid drug dependence, drug resistance, 
treatment-related side effects and to predict the outcome of 
glucocorticoid therapy in pediatric IBD patients (Lucafòet 
al. 2017). The therapeutic response to the drug etanercept, a 
TNF-α blocker, in patients with rheumatoid arthritis (RA) 
was assessed in order to increase treatment efficacy. RA pa-
tients who are genetically low TNF-α and IL-6 producers 
may be the most suitable candidates for anti-TNF-α therapy 
(Jančić et al. 2013). 
Population pharmacogenomic research has shown that 
the study of pharmacogenomic markers in various popula-
tions is of great importance. Comprehensive data repositories 
that record the prevalence of clinically relevant genomic vari-
ants in populations worldwide, including pharmacogenomic 
biomarkers, are valuable tools that can be exploited not only 
to develop guidelines for medical prioritization, but most 
importantly, to facilitate the integration of pharmacoge-
nomics into healthcare systems and to support preemptive 
pharmacogenomic testing (Viennas et al. 2016). The micro-
attribution approach was implemented in the assessment 
of the pharmacogenomic biomarkers allelic spectrum in 18 
European populations. There are significant interpopulation 
differences in pharmacogenomic biomarker allele frequen-
cies. The establishment of particular population-specific or 
European genotyping panels could be used preemptively, 
prior to or at the point of taking the required medication 
(Mizzi et al. 2017). This would be beneficial because a reduc-
tion in healthcare expenditure will be realized, but also a 
better quality of treatment of patients and, most importantly, 
better quality of patients’ lives will be achieved.
Molecular-targeted therapy
Molecular-targeted therapy is the best example of ac-
curate, causal therapy since the disease-causing molecular 
defect is a target of a drug. Most molecular-targeted therapies 
are used in the treatment of cancer. They have contributed to 
the fact that several cancers are becoming chronic diseases.
Most common translocations detected in hematological 
malignancies have been used as targets of novel molecular-
based therapies. Such is the case of the Philadelphia chro-
mosome (t(9;22)(q34;q11)), or BCR/ABL fusion, that is 
prevalently found among chronic myeloid leukemia (CML) 
patients (in 95% of cases), but is also present in ALL (in 
30%), and very rarely in some other hematological disor-
ders (Colovic et al. 2004). Imatinibmesylate is one of the first 
success stories of molecular-targeted therapy (Druker et al. 
1996). It was designed as a specific inhibitor of the aberrant 
tyrosine-kinase protein, encoded by BCR/ABL fusion. Ima-
tinibmesylate specifically binds the ATP-binding site of the 
aberrant tyrosine kinase, blocks it and prevents its activation. 
Thus it prevents uncontrolled proliferation of leukemic cells 
and introduces other homeostasis preservation mechanisms, 
such as apoptosis. Due to the application of imatinibmesylate 
in the treatment of CML and ALL patients, the cure rate, as 
well as overall survival rate, have been immensely improved. 
Another success story is noted in the treatment of a spe-
cific type of AML patients (AML-M3), or APL patients. APL 
patients are characterized by the presence of PML/RARA 
fusion (t(15;17)(q22;q21)) in more than 85% of cases. This 
PML/RARA fusion encodes the aberrant transcriptional 
factor that inactivates all RARA-dependent genes, causing 
differentiation blockage. It was found that all-trans retinoid 
acid (ATRA), a substance belonging to the group of vitamin 
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A-related compounds (retinoids), triggers PML/RARA deg-
radation, thereby activating the differentiation process and 
also causing proliferation inhibition (Degos 1992). Imatini-
bmesylate and ATRA are so far the most successful examples 
of molecular-targeted therapies, not only in leukemias but 
in all cancers.
In recent years, there have been many examples of the 
development of molecular therapeutics specific for missense, 
splice site and in-frame stop genetic variants. Due to these 
novel therapeutic strategies, the identification of gene vari-
ants has become increasingly important for the implemen-
tation of individualized treatment. It has been shown that 
carriers of certain variants should be treated with compatible 
molecular therapeutics (e.g. Kuvan for missense PAH gene 
variants). This molecular-specific therapy could become an 
important approach in future for enhancing the quality of 
life and improving the life-time of PKU-affected individuals 
(Stojiljkovic et al. 2014).
Gene therapy
Gene therapy, introducing genetic material into a cell 
to fight or prevent disease, had its beginnings over thirty 
years ago and is still considered very controversial in many 
scientific communities (Pavlovic et al. 2014). One of the first 
attempts at this therapeutic gene transfer technology was 
gene therapy of β-thalassemia syndrome, which arose as an 
answer to the many limitations of bone marrow transplanta-
tion as the only definitive cure for this monogenic disease. 
The goal of this gene therapy is the substitution of a defective 
or missing protein by introducing an intact, undamaged copy 
of the faulty gene (β-globin gene) or by induction of a gene 
that modifies the effect the defected gene has on a cell (gene 
modifiers) (Pavlovic et al. 2015). β-thalassemia modifiers 
represent promising therapeutic genes and include genes 
within (γ-globin genes) and outside globin gene loci (KLF1). 
Among the most potent modifier genes considered 
for gene therapy of β-thalassemia syndromes are γ-globin 
genes (HBG1, HBG2). Persistent expression of these fetal 
globin genes, which leads to increased production of fetal 
hemoglobin (HbF:2γ2), could ameliorate the severity of the 
β-thalassemia phenotype as γ-globin polypeptide chains 
compensate for the lack of functional β-globin chains. It is 
well documented that variants within the γ-globin gene pro-
moter can cause its overexpression and that some of them 
exert their effect under conditions of erythropoietic stress 
characteristic for β-thalassemia patients (Kollia et al. 2008; 
Ugrin et al. 2016). 
In the recent years, KLF1 emerged as a potential gene 
target for gene therapy of β-thalassemia. Namely, experi-
mental evidence suggests that variants within the KLF1 regu-
latory region can lead to reduced KLF1 transcription and 
thus to increased expression of fetal globin genes though 
the regulation of BCL11A, a known γ-globin gene repressor 
(Giardine et al. 2011; Radmilovic et al. 2013).
Gene therapy is one of the most promising approaches 
for the treatment of β-thalassemia patients. Understanding 
the mechanisms that govern human fetal globin gene switch-
ing will bring us closer to gene manipulation as a permanent 
cure for β-thalassemia syndromes and individualized therapy 
as a therapy of the future.
Stem cell and tissue therapy in personalized 
medicine
Stem cells (SCs) are undifferentiated cells with almost 
unlimited potency for self-renewal and differentiation in 
various cell types. Not long ago it was discovered that all the 
organs of our bodies have a pool of SCs serving for repopula-
tion of the cells of the organ. These cells have certain features 
making them interesting not only for research but also for 
the treatment of injuries and various diseases. The fact that 
everyone has their own pool of SCs (which can be isolated 
and propagated in vitro up to a therapeutic number at any 
moment during the lifespan) offered a specific personalized 
approach in regenerative medicine. Such individualized 
therapy overcomes most of the ethical and health issues that 
were previously connected to the application of SCs, such as 
graft versus host disease.  
Various genetic and epigenetic factors are specific for 
SCs and make them different from other cell types. The fun-
damental discovery that a cocktail of four genes is capable 
of converting differentiated adult fibroblast into pluripotent 
stem cell presented a completely new perspective in research 
and medicine (Takahashi and Yamanaka 2006). SCs have a 
potential to differentiate into various cell types. SC differen-
tiation is driven by specific molecules; either these factors are 
excreted by the cells in the specific microenvironment where 
they are injected, or the factors are added in vitro before in-
jection. SCs are capable not only of making specific cells but, 
if grown in scaffolds, constructing complete organs. This is a 
goal of tissue therapy, which is a promising prospect in stem 
cell research with personalized approach.
Among adult SCs, there is a specific population called 
mesenchymal stem cells (MSCs). MSCs are isolated from 
various tissues, such as the umbilical cord, tendon, dental 
pulp, etc. They are of mesodermal origin, but thanks to their 
plasticity, they are able to differentiate into various cell types, 
not only of mesodermal origin (neural, endothelial). They 
are easy to isolate using a minimal invasive procedure, which 
makes them very attractive for regenerative medicine. Cur-
rently, there are more than 50 clinical trials conducted to 
explore their potential in the treatment of various diseases. 
In one of these trials, the effects of usage of autologous MSCs 
isolated from the adipose tissue of patients with knee and hip 
osteoarthritis was studied. The results showed an improve-
ment in all scores that were scanned during the one-year 
follow-up period (Spasovki V, unpublished data). None of 
50    Biologia Serbica 39(1) 
Genomics as a basis for precision medicine
the patients had side effects and the quality of their everyday 
life greatly improved. None of therapies available at this mo-
ment show such efficacy and maintenance of improvement.
Nowadays, there are many diseases that can be treated 
using autologous SCs: hematopoietic diseases, osteoarthritis, 
different skin defects arising from diseases as well as from 
burns and other injuries. As our knowledge about the fea-
tures of SCs grows, it seems that treatment possibilities are 
almost unlimited. Individualized therapy, which is becoming 
the most specific trend in medicine, is something that stem 
cell therapy fulfils in all aspects. This is also why this kind of 
therapy is the therapy of the future.
Conclusion
Genomics and other -omics, like all other great break-
throughs in science, have been taken up with enthusiasm, 
but have also provoked skeptical responses among research-
ers and healthcare practitioners. The dilemma will soon be 
solved since the full integration of innovative personalized 
treatment into clinical practice is expected in next decade. 
Until then, intensive bench research continues in order to 
make its way to the patient’s bedside.
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